AMR - Asthma Medication Ratio

Product Lines:
EHP, Priority Partners and USFHP.

Eligible Population:
Members 5 - 64 years of age and older by December 31 of the measurement year. This includes Value Based Purchasing (VBP) for Priority Partners.

Definition:
The percentage of members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 50% or greater during the measurement year.

Report stratification by race and ethnicity.

Continuous Enrollment:
  • The measurement year and the year prior to the measurement year.
     

Best Practice and Measure Tips

Schedule follow-up appointments:

  • Ensure the patient is not using more rescue medications than preventive medication to control their asthma (i.e., rescue meds have 50 percent less usage than preventive meds)
  • Report the appropriate diagnosis codes for the member’s condition. Include the appropriate codes for diagnosed conditions that may exclude the member from this measure.
  • Ensure at least half of the medications dispensed to treat their asthma are controller medications throughout the treatment/measurement period. 

Patient is considered to have persistent asthma if they have any of the following:

  • At least 1 ER visit with a principal diagnosis of asthma; 
  • At least 1 acute inpatient encounter with a principal diagnosis of asthma;
  • At least 1 inpatient discharge with a principal diagnosis of asthma on the discharge claim;
  • At least 4 outpatient visits, telephone visits or e-visits or virtual check-ins, on different dates of service, with any diagnosis of asthma and at least 2 asthma medication dispensing events for any controller or reliever medication;
  • At least 4 asthma medication dispensing events for any controller or reliever medications. 

Measure Exclusions

Required Exclusions:  

  • Members who had a diagnosis that requires a different treatment approach than members with asthma any time during the member’s history through December 31 of the measurement year.
  • Members who weren’t prescribed an asthma medication any time during the measurement year.
  • Members in hospice or using hospice services anytime during the measurement year
  • Members who died any time during the measurement year.   

Exclusion Codes:

  •  Respiratory Diseases With Different Treatment Approaches Than Asthma
    • ICD-10-CM: E84.0, E84.11, E84.19, E84.8, E84.9, J43.0, J43.1, J43.2, J43.8, J43.9, J44.0, J44.1, J44.9, J68.4, J96.00, J96.01, J96.02, J96.20, J96.21, J96.22, J98.2, J98.3, 277.00, 277.01, 277.02, 277.03, 277.09, 492.0, 492.8, 493.20, 493.21, 493.22, 496, 506.4, 518.1, 518.2, 518.81. 

Measure Codes

Examples of persistent asthma codes include:

  • ICD-10-CM: J45.21, J45.22, J45.30 - J45.32, J45.40 - J45.42, J45.50 - J45.52, J45.901, J45.902, J45.909, J45.991, J45.998 

Measure Medications

Asthma Controller Medications
Description Prescription Route
Antibody inhibitors Omalizumab Injection
Anti-interleukin-4 Dupilumab Injection
Anti-interleukin-5 Benralizumab Injection
Anti-interleukin-5 Mepolizumab Injection
Anti-interleukin-5 Reslizumab Injection
Inhaled steroid combinations Budesonide-formoterol Inhalation
Inhaled steroid combinations Fluticasone-salmeterol Inhalation
Inhaled steroid combinations Fluticasone-vilanterol Inhalation
Inhaled steroid combinations Fluticasone-mometasone Inhalation
Inhaled corticosteroids Beclomethasone Inhalation
Inhaled corticosteroids Budesonide Inhalation
Inhaled corticosteroids Ciclesonide Inhalation
Inhaled corticosteroids Flunisolide Inhalation
Inhaled corticosteroids Fluticasone Inhalation
Inhaled corticosteroids Mometasone Inhalation
Leukotriene modifiers Montelukast Oral
Leukotriene modifiers Zafirlukast Oral
Leukotriene modifiers Zileuton Oral
Methylxanthines Theophylline Oral
Asthma Reliever Medications
Description Prescription Route
Short-acting, inhaled beta-2 agonists Albuterol Inhalation
Short-acting, inhaled beta-2 agonists Levalbuterol Inhalation